4 results
To study the potential of baclofen as an anti-craving/relapse agent in GHB dependent patients.
*To demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-CVP combination treatment to patients who receive MabThera®-CVP treatment. ORR will be determined during the combination treatment…
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…
PRIMARY OBJECTIVE• To compare the efficacy of Ampligen® versus control group / no treatment following FOLFIRINOX in subjects with Locally Advanced Pancreatic Adenocarcinoma.SECONDARY OBJECTIVE• To evaluate safety and tolerability of Ampligen®…